SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Paranovus Entertainment Technology Ltd. (PAVS) (CIK 0001751876) (PAVS) — Apr 17, 2023

Paranovus Entertainment Technology Ltd. (PAVS) (CIK 0001751876)
Date: April 17, 2023 · CIK: 0001751876 · Accession: 0000000000-23-003839

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 001-39098

Date
April 17, 2023
Author
Xuezhu Wang
Form
UPLOAD
Company
Paranovus Entertainment Technology Ltd. (PAVS) (CIK 0001751876)

Letter

United States securities and exchange commission logo April 17, 2023 Xuezhu Wang Chief Executive Officer Paranovus Entertainment Technology Ltd. No. 11, Dongjiao East Road, Shuangxi, Shunchang, Nanping City Fujian Province, People’s Republic of China Re:Paranovus Entertainment Technology Ltd. Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2022 Filed August 15, 2022 File No. 001-39098 Dear Xuezhu Wang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joan Wu, Esq.

Show Raw Text
United States securities and exchange commission logo
April 17, 2023
Xuezhu Wang
Chief Executive Officer
Paranovus Entertainment Technology Ltd.
No. 11, Dongjiao East Road, Shuangxi, Shunchang, Nanping City
Fujian Province, People’s Republic of China
Re:Paranovus Entertainment Technology Ltd.
Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2022
Filed August 15, 2022
File No. 001-39098
Dear Xuezhu Wang:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Joan Wu, Esq.